TEDALINAB

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H21F2N3O
Molecular Weight	345.3863
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CC[C@@]([H])(C1)C3=C2N(N=C3C(=O)NC(C)(C)C)C4=C(F)C=C(F)C=C4

InChI

InChIKey=NTPZXHMTJGOMCJ-WDEREUQCSA-N

InChI=1S/C19H21F2N3O/c1-19(2,3)22-18(25)16-15-10-4-5-11(8-10)17(15)24(23-16)14-7-6-12(20)9-13(14)21/h6-7,9-11H,4-5,8H2,1-3H3,(H,22,25)/t10-,11+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C19H21F2N3O
Molecular Weight	345.3863
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28464443 https://pipelinereview.com/index.php/2008071520951/Small-Molecules/Glenmarks-molecule-for-Neuropathic-Pain-Osteoarthritis-GRC-10693-to-enter-Phase-I-trials-GRC-10693-is-Glenmarks-fifth-molecule-to-enter-clinical-trials.html | https://www.financialexpress.com/archive/glenmark-completes-phase-i-trial-of-grc-10693/446437/

Glenmark Pharmaceuticals has developed tedalinab (also known as GRC-10693) as a potent and selective cannabinoid CB2 receptor agonist for the treatment of osteoarthritis and neuropathic pain. In April 2009, Glenmark announced that tedalinab indicated for the treatment of neuropathic, osteoarthritis and other inflammatory pain disorders had successfully completed Phase I trials in Europe. The drug was ready for phase II of trials; however, information about the further development of this drug is not available.

Originator

Approval Year

PubMed

Title	Date	PubMed
The Drug Discovery and Development Industry in India-Two Decades of Proprietary Small-Molecule R&D.	2017 Jun 7	28464443

Patents

Sample Use Guides

In Vivo Use Guide

300 mg of GRC 10693 (Tedalinab) once daily for 14 days

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 17 07:34:21 UTC 2022` Edited by `admin` on `Sat Dec 17 07:34:21 UTC 2022`
Record UNII	5R7X34Y6Q1
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TEDALINAB

Official Name

English

GRC10693

Code

English

GRC-10693

Code

English

tedalinab [INN]

Common Name

English

(4S,7R)-N-TERT-BUTYL-1-(2,4-DIFLUOROPHENYL)-4,5,6,7-TETRAHYDRO-1H-4,7-METHANOINDAZOLE-3-CARBOXAMIDE

Systematic Name

English

Tedalinab [WHO-DD]

Common Name

English

4,7-METHANO-1H-INDAZOLE-3-CARBOXAMIDE, 1-(2,4-DIFLUOROPHENYL)-N-(1,1-DIMETHYLETHYL)-4,5,6,7-TETRAHYDRO-, (4S,7R)-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C257